Key clinical point: Trastuzumab and pertuzumab can be safely added to neoadjuvant CRT for resectable HER2-positive esophageal adenocarcinoma, with apparent good efficacy.

Major finding: Fully 83% of patients completed the neoadjuvant combination. All patients undergoing surgery achieved R0 resection and 34% achieved pCR; 3-year rates of progression-free and overall survival were 72% and 71%, respectively.

Study details: A multicenter, single-arm phase 2 trial among 40 patients with resectable HER2-positive adenocarcinoma of the esophagus or gastroesophageal junction (TRAP trial).

Disclosures: Dr. van Laarhoven disclosed honoraria from Lilly/ImClone; a consulting or advisory role with Lilly/ImClone, Nordic Group, Bristol-Myers Squibb, and Servier; research funding from numerous pharmaceutical companies; and travel, accommodations, and/or expenses from AstraZeneca. The study was supported by the Academic Medical Center, Amsterdam, and by an unrestricted research grant from Hoffmann-LaRoche, Basel, Switzerland.